These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27942008)

  • 1. The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.
    Dietrich N; Kolibabka M; Busch S; Bugert P; Kaiser U; Lin J; Fleming T; Morcos M; Klein T; Schlotterer A; Hammes HP
    PLoS One; 2016; 11(12):e0167853. PubMed ID: 27942008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy.
    Kolibabka M; Dietrich N; Klein T; Hammes HP
    Diabetologia; 2018 Nov; 61(11):2412-2421. PubMed ID: 30097694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy.
    Oezer K; Kolibabka M; Gassenhuber J; Dietrich N; Fleming T; Schlotterer A; Morcos M; Wohlfart P; Hammes HP
    Acta Diabetol; 2023 Nov; 60(11):1551-1565. PubMed ID: 37423944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
    Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
    Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture.
    Li H; Zhang J; Lin L; Xu L
    Int Immunopharmacol; 2019 Jan; 66():162-168. PubMed ID: 30466028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
    Terawaki Y; Nomiyama T; Kawanami T; Hamaguchi Y; Takahashi H; Tanaka T; Murase K; Nagaishi R; Tanabe M; Yanase T
    Cardiovasc Diabetol; 2014 Nov; 13():154. PubMed ID: 25407968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.
    Wongchai K; Schlotterer A; Lin J; Humpert PM; Klein T; Hammes HP; Morcos M
    Horm Metab Res; 2016 Jan; 48(1):70-5. PubMed ID: 25951323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.
    Kosaraju J; Holsinger RMD; Guo L; Tam KY
    Mol Neurobiol; 2017 Oct; 54(8):6074-6084. PubMed ID: 27699599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
    Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
    J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylglyoxal induces retinopathy-type lesions in the absence of hyperglycemia: studies in a rat model.
    Schlotterer A; Kolibabka M; Lin J; Acunman K; Dietrich N; Sticht C; Fleming T; Nawroth P; Hammes HP
    FASEB J; 2019 Mar; 33(3):4141-4153. PubMed ID: 30485119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
    Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
    Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats.
    Łupina M; Talarek S; Kotlińska J; Gibuła-Tarłowska E; Listos P; Listos J
    Neurochem Int; 2020 Feb; 133():104616. PubMed ID: 31809774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
    J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.
    Miglio G; Vitarelli G; Klein T; Benetti E
    Br J Pharmacol; 2017 May; 174(9):809-821. PubMed ID: 28177527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.